Thus, we sought to assess the expression profiles of NLRP3, CASP1, and IL‐1β in pediatric blood cancer samples, reasoning that the largest therapeutic impact of NLRP3 inhibition on cancer progression likely occurs in leukemia subtypes with the highest expression levels. The gene discussed is NLRP3; the disease is leukemia.